A phase I study Analyzing Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment
Latest Information Update: 01 Sep 2022
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 01 Sep 2022 New trial record
- 29 Aug 2022 Results published in the European Journal of Drug Metabolism and Pharmacokinetics